Aligos Therapeutics, Inc. Deferred Revenue
Aligos Therapeutics, Inc. (ALGS) had Deferred Revenue of $0 as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-03-05
- 2025-12-31: Deferred Revenue, Current $0.00.
- 2025-09-30: Deferred Revenue, Current $168.00K.
- 2025-06-30: Deferred Revenue, Current $579.00K.
- 2024-12-31: Deferred Revenue, Current $151.00K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-05 |
| 2025-09-30 | $168.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $579.00K 10-Q · filed 2025-08-06 |
| 2024-12-31 | $151.00K 10-K · filed 2026-03-05 |
| 2023-12-31 | $1.31M 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |